Laser Iridotomy Versus Phacoemulsification in Acute Angle Closure (NCT00350428) | Clinical Trial Compass
CompletedNot Applicable
Laser Iridotomy Versus Phacoemulsification in Acute Angle Closure
Singapore70 participantsStarted 2001-10
Plain-language summary
This is a randomised controlled clinical trial to compare laser peripheral iridotomy (LPI) and primary phacoemulsification with intra-ocular lens implantation (phaco/IOL) in the treatment of acute primary angle-closure glaucoma (APACG). Following successful medical lowering of raised intra-ocular pressure (IOP) and control of intraocular inflammation, patients presenting to Singapore National Eye Centre and Singapore General Hospital with acute primary angle-closure glaucoma who meet the eligibility are randomised to one of the two treatment arms: laser peripheral iridotomy and primary phacoemulsification with intra-ocular lens implantation. These patients will be monitored closely for 2 years post-operatively.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. APACG. In cases where both eyes are eligible, the right eye will be entered.
✓. IOP less than or equal to 30 mmHg within 24 hours of presentation and after initiation of medical treatment
✓. Significant cataract with best corrected visual acuity equal or less than 6/15
✓. Informed consent
Exclusion criteria
✕. Secondary causes of angle-closure e.g. subluxed lens, uveitis, trauma and neovascular glaucoma
✕. Intumescent cataract (phacomorphic glaucoma)
✕. Eyes with anterior chamber depth differing by more than 0.3 mm
✕. Eyes with no cataract
✕. Active ocular infection in either eye which would prevent surgery
✕. Female subjects who are pregnant, nursing or of childbearing potential and not using adequate contraception
What they're measuring
1
Recurrence of APACG: Patients who develop a recurrence of symptoms of APACG. Treatment of recurrence will be decided by the ophthalmologist managing the patient.